QuidelOrtho Corporation stock rallied sharply in morning trading after the company posted quarterly earnings per share of $0.80, compared with a consensus analyst estimate of $0.51. The outsized earnings print helped signal to investors that the San Diego-based diagnostics firm may be emerging from the significant operational and market pressures that weighed on its first quarter of 2026.
The company’s Q1 performance had been a difficult stretch. Revenue for the quarter came in at $619.8 million, below expectations, a shortfall the company attributed in part to a notably weaker respiratory season and to pressure from proposed reductions to reimbursement rates in China. Those headwinds contributed to a wave of negative analyst actions after the Q1 miss.
Following the revenue shortfall, a number of major brokerages adjusted their outlooks for the stock. JPMorgan reduced its price target to $11, UBS cut its target to $12, Citi lowered its view to $13, and Jefferies downgraded the stock to Hold with a $12.50 target. Those revisions left the shares trading close to their 52-week low of $9.92 ahead of today’s move, in contrast with a consensus 12-month price target of roughly $18.63 from the Street.
Investors also pointed to an external catalyst that favored companies with established diagnostic capabilities. A global Hantavirus outbreak linked to the MV Hondius cruise ship involving the Andes strain - the only hantavirus known to transmit person-to-person - has driven renewed interest in firms that operate molecular and antigen testing platforms. QuidelOrtho’s product mix, which spans point-of-care diagnostics, molecular testing, and laboratory solutions, positions the company as a potential beneficiary should governments expand pathogen surveillance protocols.
Market breadth helped the stock’s advance. The NASDAQ composite rose 1.2% on the session and the S&P 500 gained 0.8%, providing a constructive macro backdrop that coincided with the company-specific news flow. Those conditions combined with the earnings surprise and the previously compressed valuation to produce a significant single-session move for the shares.
During the session, QuidelOrtho reached an intraday high of $19.80, a sharp rebound from levels near the year low but still well under its 52-week high of $35.58. The gap between the current trading level and the one-year peak leaves scope for further recovery should the operational improvement persist into the second half of 2026, though the article reflects only the facts reported to date.
Key data points referenced in this report are company-reported EPS of $0.80 versus $0.51 expected, Q1 revenue of $619.8 million, analyst price target revisions to $11, $12, $13 and $12.50 at JPMorgan, UBS, Citi and Jefferies respectively, a consensus 12-month price target near $18.63, intraday high of $19.80, 52-week low of $9.92 and 52-week high of $35.58.